Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Current Assets (2016 - 2025)

Vanda Pharmaceuticals' Current Assets history spans 16 years, with the latest figure at $347.3 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 20.88% to $347.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $347.3 million, a 20.88% decrease, with the full-year FY2025 number at $347.3 million, down 20.88% from a year prior.
  • Current Assets hit $347.3 million in Q4 2025 for Vanda Pharmaceuticals, down from $367.5 million in the prior quarter.
  • Over the last five years, Current Assets for VNDA hit a ceiling of $536.6 million in Q3 2023 and a floor of $347.3 million in Q4 2025.
  • Historically, Current Assets has averaged $456.4 million across 5 years, with a median of $443.0 million in 2021.
  • Biggest five-year swings in Current Assets: rose 18.55% in 2021 and later fell 20.88% in 2025.
  • Tracing VNDA's Current Assets over 5 years: stood at $478.3 million in 2021, then rose by 8.57% to $519.3 million in 2022, then fell by 16.63% to $432.9 million in 2023, then increased by 1.37% to $438.9 million in 2024, then fell by 20.88% to $347.3 million in 2025.
  • Business Quant data shows Current Assets for VNDA at $347.3 million in Q4 2025, $367.5 million in Q3 2025, and $394.9 million in Q2 2025.